Cover Image
市場調查報告書

創傷:開發平台評估

Wounds - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255970
出版日期 內容資訊 英文 236 Pages
訂單完成後即時交付
價格
Back to Top
創傷:開發平台評估 Wounds - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 236 Pages
簡介

創傷是因為手術、受傷、化學藥品、熱或冷氣的接觸、摩擦、壓力或是下肢潰瘍和癌症等疾病的影響,造成皮膚及皮下組織受損並引起皮膚保護功能受損(上皮組織的連續性損壞),或皮下接合組織(肌肉、骨骼、神經)受損等。症狀有傷口周圍發紅或是紅色線狀、腫起、分泌出膿狀液體、惡臭、惡寒、發燒等。有服用抗生素等治療法。

本報告網羅全球傷口護理藥開發平台資訊,提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的商品評估等。

目錄

簡介

  • 分析範圍

創傷概要

治療藥的開發

  • 創傷開發中產品:概要
  • 創傷開發中產品:比較分析

創傷:正在開發的治療藥:各企業

創傷:正在開發的治療藥:大學·研究機關別

創傷:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

創傷:開發中的產品:各企業

創傷:開發中的產品:大學·研究機關別

創傷:治療藥的開發企業

  • Cardium Therapeutics, Inc.
  • Smith & Nephew Plc
  • Sanofi
  • Biotec Pharmacon ASA
  • Kuros Biosurgery AG
  • Pharming Group N.V.
  • Stratatech Corporation
  • Photopharmica Limited
  • Tissue Repair Company
  • Nanotherapeutics, Inc.
  • Octapharma AG
  • Apricus Biosciences, Inc.
  • Bio3 Research S.r.l
  • NeoStem, Inc.
  • HanAll Biopharma Co., Ltd.
  • Sucampo Pharmaceuticals, Inc.
  • CytoTools AG
  • CYATHUS EXQUIRERE PharmaforschungsGmbH
  • MetrioPharm AG
  • Dongkook Pharmaceutical Co., Ltd.
  • Juventas Therapeutics, Inc.
  • Omnio Healer AB
  • ConjuGon, Inc.
  • Garnet BioTherapeutics
  • Gene Signal International SA
  • AndroScience Corporation
  • GliaMed, Inc.
  • Omeros Corporation
  • NanoBio Corporation
  • FirstString Research, Inc.
  • Molecular Design International, Inc.
  • Sirnaomics, Inc.
  • SunTen Phytotech Co., Ltd.
  • miRagen Therapeutics, Inc.
  • Pacific Northwest Biotechnology, LLC
  • Beech Tree Labs, Inc.
  • Mirrx Therapeutics A/S
  • EyeGene, Inc.
  • Neumedicines Inc.
  • AlgiPharma AS
  • SomaGenics Inc.
  • Advancell
  • Birken AG
  • Provasculon, Inc.
  • Pergamum AB
  • Microbion Corporation
  • Escape Therapeutics, Inc.
  • Kasiak Research Pvt. Ltd.
  • Regenics AS
  • vida therapeutics inc.
  • Hemostemix Ltd

創傷:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • MB-11316
  • dokishisaikurin
  • GAM-501
  • DermaPro CL-05
  • GBT-009
  • HP-802247
  • StrataGraft Skin Tissue
  • KUR-212
  • PPA-904
  • Granexin
  • CSTC-1
  • Evitar
  • JVS-100
  • Mesenchymal Cells For Wound Care
  • Bismuth ethanedithiol
  • MALP-2
  • KUR-213
  • GM-1485
  • CTR-2
  • cobiprostone
  • alprostadil
  • ASCJ-9
  • MDI-301
  • GS-156
  • Soluble Beta Glucan
  • MGN-4220
  • STP-705
  • BTL-slo
  • NB-201
  • RNAi Oligonucleotide To Inhibit VE-Cadherin For Inflammation, Ischemia and Wound Healing
  • NMIL-121
  • Vasculotide
  • AKB-4924
  • Neurotensin
  • C-31510
  • MP-1031
  • Peptides for Dermatology and Infectious Disease
  • CM-101
  • Stem Cell Therapy for Chronic Wound Healing and Scleroderma
  • ANs-31
  • HL-156Fib
  • AlloGraf
  • GN-4474
  • HDFx
  • Drugs to Agonize c-Met for Wound
  • EG-Decorin
  • Bismith-Thiol Compound For Chronic Wound Infection
  • Stem Cell Therapy for Wounds
  • Small Molecule For Acute Wound Care
  • AG-30/5C
  • Recombinant Plasminogen
  • Vernex
  • V-2248
  • Migration Stimulating Factor
  • STD-06
  • Proteins to Inhibit SEB and TSST-1 for Infectious Disease, Infectious Disease, Shock and Respiratory Disorders
  • NL-005
  • hVGF
  • PGF
  • Small Molecule Antagonists to Transforming Growth Factor Beta Receptor for Alopecia, Pulmonary Fibrosis and Dermatology
  • Nu-2
  • PRF-65339
  • A3-APO
  • BCI
  • Chordin
  • Human Soluble CD-146
  • phenytoin
  • pyrvinium chloride
  • Cyathus-1102-B
  • Stem Cell Therapy for Wound Healing
  • DNA Pro-Drug Program
  • Monoclonal Antibody Gel for Inflammation, Burns and Wounds
  • CA5-HIF Gene Therapy for Wound and Ulcers
  • Drug to Inhibit 11ß-HSD1 for Wound Healing
  • Adipose Stem Cell Therapy For Skin Wound
  • Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound
  • NVN-4428
  • Recombinant Human Collagen Type 1
  • OligoG For Wounds And Burns
  • Small Molecule Targeting LGR6 for Wound Repair and Formation of New Hair Follicles
  • Asiaticoside Derivatives
  • GP-505
  • Enzyme for Dermatology and Infectious Diseases
  • Cell Therapy for Wounds
  • Fibroblast Growth Factor Conjugate
  • PXL-181
  • RNAi Oligonucleotide for Wound Healing
  • Wound Healing Program
  • Sugar-Free Fibroblast Growth Factor
  • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders
  • BCP-01
  • Refaheal
  • Human Growth Factor
  • Recombinant Plasminogen
  • XEN-103
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7310IDB

Summary

Global Markets Direct's, 'Wounds - Pipeline Review, H2 2015', provides an overview of the Wounds's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Wounds
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Wounds
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wounds Overview
  • Therapeutics Development
    • Pipeline Products for Wounds - Overview
    • Pipeline Products for Wounds - Comparative Analysis
  • Wounds - Therapeutics under Development by Companies
  • Wounds - Therapeutics under Investigation by Universities/Institutes
  • Wounds - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Wounds - Products under Development by Companies
  • Wounds - Products under Investigation by Universities/Institutes
  • Wounds - Companies Involved in Therapeutics Development
    • Advancell
    • Aerpio Therapeutics, Inc.
    • AlgiPharma AS
    • AndroScience Corporation
    • AnGes MG, Inc.
    • Aridis Pharmaceuticals LLC
    • Beech Tree Labs, Inc.
    • Berg LLC
    • Bio3 Research S.r.l
    • Biokine Therapeutics Ltd.
    • Biotec Pharmacon ASA
    • Birken AG
    • Blueberry Therapeutics Ltd
    • Caladrius Biosciences, Inc.
    • Cellphire, Inc.
    • CorMedix, Inc.
    • Destiny Pharma Limited
    • FibroGen, Inc.
    • Foresee Pharmaceuticals, LLC
    • GangaGen Inc.
    • Gene Signal International SA
    • GlaxoSmithKline Plc
    • HanAll Biopharma Co., Ltd.
    • IntelliCell BioSciences Inc.
    • Juventas Therapeutics, Inc.
    • Kuros Biosurgery AG
    • LegoChem Biosciences, Inc
    • Living Cell Technologies Limited
    • Molecular Design International, Inc.
    • NatureWise Biotech & Medicals Corporation
    • Novan, Inc.
    • Nuvo Research Inc.
    • Octapharma AG
    • Omeros Corporation
    • Pacific Northwest Biotechnology, LLC
    • ProMetic Life Sciences Inc.
    • Regenics AS
    • RXi Pharmaceuticals Corporation
    • Sanofi
    • SomaGenics Inc.
    • Stratatech Corporation
    • Sucampo Pharmaceuticals, Inc.
    • Symic Biomedical, Inc.
    • TGV-Laboratories
    • Thesan Pharmaceuticals, Inc.
    • TumorEnd, LLC
    • VBS Pharmaceuticals
    • Vida Therapeutics Inc.
  • Wounds - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-3APO - Drug Profile
    • Adipose Stem Cell Therapy for Skin Wound - Drug Profile
    • AG-30/5C - Drug Profile
    • AKB-4924 - Drug Profile
    • ALLO-ASC - Drug Profile
    • ANs-31 - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile
    • APO-2 - Drug Profile
    • AR-101 - Drug Profile
    • Arginine Butyrate - Drug Profile
    • ARN-077 - Drug Profile
    • ASCJ-9 - Drug Profile
    • Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound - Drug Profile
    • Autologous Vascular Cells Therapy - Drug Profile
    • BB-1000 - Drug Profile
    • Biosimilar for Diabetic Wounds - Drug Profile
    • BKT-170 - Drug Profile
    • BTL-slo - Drug Profile
    • CAR Peptide - Drug Profile
    • Cell Therapy for Dermatology and Immunology - Drug Profile
    • Cell Therapy for Wounds - Drug Profile
    • CM-101 - Drug Profile
    • cobiprostone - Drug Profile
    • CR-2016 - Drug Profile
    • CRMD-004 - Drug Profile
    • CTR-2 - Drug Profile
    • daprodustat - Drug Profile
    • DB-2121 - Drug Profile
    • Drug for Dermatology and Infectious Diseases - Drug Profile
    • Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile
    • Drugs to Activate iRhom2 for Wound Healing and Cancer - Drug Profile
    • Drugs to Agonize c-Met for Wounds - Drug Profile
    • Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile
    • FG-6874 - Drug Profile
    • FP-009 - Drug Profile
    • Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
    • GS-156 - Drug Profile
    • HL-156FIB - Drug Profile
    • Human Growth Factor - Drug Profile
    • hVGF - Drug Profile
    • JM-2 - Drug Profile
    • JVS-100 - Drug Profile
    • KL-7016 - Drug Profile
    • KUR-213 - Drug Profile
    • LCB-030110 - Drug Profile
    • LWnt-3a - Drug Profile
    • MDI-301 - Drug Profile
    • Mesenchymal Cells for Wound Care - Drug Profile
    • MG-53 - Drug Profile
    • MMP-26051 - Drug Profile
    • MMP-26052 - Drug Profile
    • Monoclonal Antibody Conjugated for Burns and Wounds - Drug Profile
    • Mul-1867 - Drug Profile
    • NBM-67 - Drug Profile
    • ND-336 - Drug Profile
    • NTCELL - Drug Profile
    • OleogelS-10 - Drug Profile
    • Oligomer G for Wounds And Burns - Drug Profile
    • Oxofoam - Drug Profile
    • P-128 - Drug Profile
    • Panaecin - Drug Profile
    • Pelladerm - Drug Profile
    • Peptide for Wounds - Drug Profile
    • perflenapent for wound healing - Drug Profile
    • Perlecan - Drug Profile
    • PGF - Drug Profile
    • plasminogen (recombinant) - Drug Profile
    • Polysaccharide for Wounds and Scars - Drug Profile
    • Protein for Diabetic Wound Healing - Drug Profile
    • Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile
    • Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile
    • Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
    • Protein to Inhibit SEB and TSST-1 for Infectious Disease, Dermatology, Respiratory Disorders and Other Diseases - Drug Profile
    • Recombinant Erythropoetin For Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
    • Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile
    • Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
    • RNAi Oligonucleotide for Wound Healing - Drug Profile
    • Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles - Drug Profile
    • Small Molecules for Wounds and Scars - Drug Profile
    • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
    • Soluble Beta Glucan - Drug Profile
    • Stem Cell Therapy for Wound Healing - Drug Profile
    • Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
    • Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds - Drug Profile
    • Synthetic Peptides to Activate VEGF for Wound Healing and Neurodegenerative Diseases - Drug Profile
    • Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
    • Thrombosomes - Drug Profile
    • TRT-8174 - Drug Profile
    • ubidecarenone - Drug Profile
    • V-2248 - Drug Profile
    • Vernex - Drug Profile
    • VRP-017 - Drug Profile
    • VTI-3000 Series - Drug Profile
    • XF-70 - Drug Profile
  • Wounds - Recent Pipeline Updates
  • Wounds - Dormant Projects
  • Wounds - Discontinued Products
  • Wounds - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wounds, H2 2015
  • Number of Products under Development for Wounds - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Wounds - Pipeline by Advancell, H2 2015
  • Wounds - Pipeline by Aerpio Therapeutics, Inc., H2 2015
  • Wounds - Pipeline by AlgiPharma AS, H2 2015
  • Wounds - Pipeline by AndroScience Corporation, H2 2015
  • Wounds - Pipeline by AnGes MG, Inc., H2 2015
  • Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2015
  • Wounds - Pipeline by Beech Tree Labs, Inc., H2 2015
  • Wounds - Pipeline by Berg LLC, H2 2015
  • Wounds - Pipeline by Bio3 Research S.r.l, H2 2015
  • Wounds - Pipeline by Biokine Therapeutics Ltd., H2 2015
  • Wounds - Pipeline by Biotec Pharmacon ASA, H2 2015
  • Wounds - Pipeline by Birken AG, H2 2015
  • Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2015
  • Wounds - Pipeline by Caladrius Biosciences, Inc. , H2 2015
  • Wounds - Pipeline by Cellphire, Inc., H2 2015
  • Wounds - Pipeline by CorMedix, Inc., H2 2015
  • Wounds - Pipeline by Destiny Pharma Limited, H2 2015
  • Wounds - Pipeline by FibroGen, Inc., H2 2015
  • Wounds - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
  • Wounds - Pipeline by GangaGen Inc., H2 2015
  • Wounds - Pipeline by Gene Signal International SA, H2 2015
  • Wounds - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Wounds - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Wounds - Pipeline by IntelliCell BioSciences Inc., H2 2015
  • Wounds - Pipeline by Juventas Therapeutics, Inc., H2 2015
  • Wounds - Pipeline by Kuros Biosurgery AG, H2 2015
  • Wounds - Pipeline by LegoChem Biosciences, Inc, H2 2015
  • Wounds - Pipeline by Living Cell Technologies Limited, H2 2015
  • Wounds - Pipeline by Molecular Design International, Inc., H2 2015
  • Wounds - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015
  • Wounds - Pipeline by Novan, Inc., H2 2015
  • Wounds - Pipeline by Nuvo Research Inc., H2 2015
  • Wounds - Pipeline by Octapharma AG, H2 2015
  • Wounds - Pipeline by Omeros Corporation, H2 2015
  • Wounds - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015
  • Wounds - Pipeline by ProMetic Life Sciences Inc., H2 2015
  • Wounds - Pipeline by Regenics AS, H2 2015
  • Wounds - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
  • Wounds - Pipeline by Sanofi, H2 2015
  • Wounds - Pipeline by SomaGenics Inc., H2 2015
  • Wounds - Pipeline by Stratatech Corporation, H2 2015
  • Wounds - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
  • Wounds - Pipeline by Symic Biomedical, Inc., H2 2015
  • Wounds - Pipeline by TGV-Laboratories, H2 2015
  • Wounds - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015
  • Wounds - Pipeline by TumorEnd, LLC, H2 2015
  • Wounds - Pipeline by VBS Pharmaceuticals, H2 2015
  • Wounds - Pipeline by Vida Therapeutics Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Wounds Therapeutics - Recent Pipeline Updates, H2 2015
  • Wounds - Dormant Projects, H2 2015
  • Wounds - Dormant Projects (Contd..1), H2 2015
  • Wounds - Dormant Projects (Contd..2), H2 2015
  • Wounds - Dormant Projects (Contd..3), H2 2015
  • Wounds - Dormant Projects (Contd..4), H2 2015
  • Wounds - Dormant Projects (Contd..5), H2 2015
  • Wounds - Dormant Projects (Contd..6), H2 2015
  • Wounds - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Wounds, H2 2015
  • Number of Products under Development for Wounds - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top